Vertebral body resection for epidural compression by malignant tumors. Results of forty-seven consecutive operative procedures.Tzony Siegal, Petah Tiqva, Tzony Siegal|Journal of Bone and Joint Surgery|1985 We are presenting our experience with vertebral body resection in forty-seven operative procedures in forty patients with a malignant epidural tumor. The indication for surgery was neural relapse after previous radiotherapy in eighteen procedures, the need for a tissue diagnosis in sixteen, a radioresistant tumor in seven, neural deterioration while receiving radiotherapy in five, and a pathological fracture-dislocation in one. In thirty-three procedures (70 per cent) the level of compression was in the thoracic spine. Replacement of the resected vertebral bodies was achieved by anterior instrumentation and the use of methylmethacrylate in twenty-one procedures (45 per cent), while bone-grafting, cement, and instrumentation in various combinations were used in the remainder. Before surgery all of the patients had some neural deficit. The patient was still able to walk prior to twelve (26 per cent) of the procedures, was paraparetic prior to twenty-three (49 per cent), and was paraplegic prior to twelve (26 per cent). Bowel and bladder dysfunction was present before twenty-five (53 per cent). The outcome of only forty-four procedures could be evaluated because three patients died postoperatively. The patient was able to walk following thirty-five (80 per cent) of the procedures, was paraparetic after eight (18 per cent), and was still paraplegic after one. The patient regained normal sphincter control after forty-one (93 per cent) of the procedures. Three (6 per cent) of the procedures were followed by the death of the patient, and complications occurred after five (11 per cent) of the procedures.(ABSTRACT TRUNCATED AT 250 WORDS)
Subacute Central Nervous System Degeneration in a Child: An Unusual Manifestation of Ifosfamide IntoxicationAvinoam Shuper, Jeremiah Stein, Jacob Goshen et al.|Journal of Child Neurology|2000 A 5-year-old child with desmoplastic small round-cell tumor was treated with a protocol of very-high-dose, short-term chemotherapy, containing HD-CAV (cyclophosphamide, doxorubicin, vincristine, and mesna), ifosfamide, and etoposide. Two days after the initiation of ifosfamide, he exhibited new-onset lethal encephalopathy manifested by subacutely progressive cerebellar and then temporal and frontocortical degeneration leading to a vegetative state and eventually to death. A full work-up, including brain biopsy, was negative, excluding infections and metabolic or vascular causes. Ifosfamide is known to be capable of causing acute encephalopathy that can be severe but is generally reversible. This child showed a very atypical progressive, lethal course of ifosfamide toxicity. The possibility of this complication should be considered when high-dose ifosfamide treatment is planned for children.
NO RESPONSE TO RECOMBINANT HUMAN ERYTHROPOIETIN THERAPY IN PATIENTS WITH CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE IHannah Tamary, Petah Tiqva, Hanna Shalev et al.|Pediatric Hematology and Oncology|1999 Congenital dyserythropoietic anemia (CDA) type I is a rare inherited bone marrow disorder characterized by moderate to severe macrocytic anemia with pathognomonic cytopathology of nucleated red blood cells. Previous studies have suggested that serum erythropoietin levels in affected patients are lower than expected for the degree of anemia. An earlier study demonstrated a substantial increase in the number of CFU-E in CDA type I pattern on addition of exogenous erythropoietin. The present study reports on the response to recombinant human erythropoietin in 8 patients with CDA type I. Eighteen weeks of treatment, starting at 300 IU/kg twice a week and gradually increasing to 500 IU/kg three times a week, did not have a substantial effect on the mean hemoglobin value. These results indicate that recombinant human erythropoietin (rHuEpo) is not beneficial to patients with CDA type I and that the relatively low levels of serum erythropoietin probably play no major role in the pathogenesis of the disease.
Further Observations on Citral-Induced Changes in the Ventral Prostate of the RatC Servadio, A. Abramovici, Joseph Schmueli et al.|The Journal of Urology|1987 No AccessJournal of Urology1 Jun 1987Further Observations on Citral-Induced Changes in the Ventral Prostate of the Rat Ciro Servadio, Armand Abramovici, Joseph Schmueli, Uri Sandbank, and Petah Tiqva Ciro ServadioCiro Servadio More articles by this author , Armand AbramoviciArmand Abramovici More articles by this author , Joseph SchmueliJoseph Schmueli More articles by this author , Uri SandbankUri Sandbank More articles by this author , and Petah TiqvaPetah Tiqva More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)76211-8AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Further Observations on Citral-Induced Changes in the Ventral Prostate of the Rat." The Journal of Urology, 137(6), p. 369A © 1987 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 137Issue 6June 1987Page: 369A Advertisement Copyright & Permissions© 1987 by The American Urological Association Education and Research, Inc.MetricsAuthor Information Ciro Servadio More articles by this author Armand Abramovici More articles by this author Joseph Schmueli More articles by this author Uri Sandbank More articles by this author Petah Tiqva More articles by this author Expand All Advertisement PDF downloadLoading ...
Rheomacrodex in the prevention of intraperitoneal adhesions. Experimental work in cats.